Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2000-05-26
2009-10-13
Saoud, Christine J (Department: 1649)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S142100, C424S135100, C424S136100, C424S130100, C530S388100, C530S388220
Reexamination Certificate
active
07601352
ABSTRACT:
Monoclonal antibodies, synthetic and biotechnological derivatives thereof (ScFv or others) are able to recognize the NGF high affinity receptor, TrkA, and act as NGF-antagonist molecules. Pharmacological compositions for therapy, gene therapy, diagnostics of neurological pathologies are also described. Transgenic animal models to study such pathologies are also described.
REFERENCES:
patent: DD296964 (1991-12-01), None
patent: 0 471 205 (1992-02-01), None
patent: WO 95/15180 (1995-06-01), None
patent: WO9710354 (1997-03-01), None
Rudikoff et al. Proc Natl. Acad. Sci. USA 1982 vol. 79: p. 1979.
Kramer et al. Eur J. Cancer 1997. 33: 2090-91.
Hudson et al. J. Immunol. Method. 1999. 231:177-189.
Peterson et al. DNA and Cell Biol. 1998. 17: 1031-1040.
Gomi et al. Proc. Natl. Acad. Sci. USA. 1994. 91: 2824-2828.
Urfer et al. J. Biol. Chem. 1998. 273:5829-5840.
Debeir et al., “A nerve growth factor mimetic TrkA antagonist causes withdrawal of cortical cholinergic boutons in the adult rat.”, Proceedings of the National Academy of Sciences of the United States of America, vol. 96 pp. 4067-4072 (1999).
LeSauteur et al., “Potent Human P140-TrkA Agonists Derived from an Anti-receptor Monoclonal Antibody”, Journal of Neuroscience, U.S., New York, NY., vol. 16, No. 4, pp. 1308-1316 (1996).
Cattaneo et al., “Functional blockade of tyrosine kinase A in the rat basal forebrain by a novel antagonistic anti-receptor monoclonal antibody.”, Journal of Neuroscience, vol. 19, No. 22, pp. 9687-9697, (1999).
Camoratto, et al., “CEP-751 Inhibits TRK Receptor Tyrosine Kinase Activity in vitro and Exhibits Anti-Tumor Activity,” Int. J. Cancer (1997), vol. 72, pp. 673-679.
Cattaneo, et al., “Functional Blockade of Tyrosine Kinase A in the Rat Basal Forebrain by a Novel Antagonistic Anti-Receptor Monoclonal Antibody,” The Journal of Neuroscience (1999), vol. 19(22), pp. 9687-9697.
Chen, et al., “A Chemical-Genetic Approach to Studying Neurotrophin Signaling,” Neuron (2005), vol. 46, pp. 13-21.
Clary, et al., “TrkA Cross-linking Mimics Neuronal Responses to Nerve Growth Factor,” Molecular Biology of the Cell (1994), vol. 5, pp. 549-563.
Coulier, et al., “Human trk Oncogenes Activated by Point Mutation, In-Frame Deletion, and Duplication of the Tyrosine Kinase Domain,” Molecular and Cellular Biology (1990), vol. 10, pp. 4202-4210.
Covaceuszach, et al., “Neutralilzation of NGF-TrkA Receptor Interaction by the Novel Antagonistic Anti-TrkA Monoclonal Antibody MNAC13: A Structural Insight,” Proteins: Structure, Function, and Bioinformatics (2005), vol. 58, pp. 717-727.
Cunningham and Greene, “A function-structure model for NGF-activated TRK,” The EMBO Journal (1998), vol. 17, No. 24, pp. 7282-7293.
Hempstead, et al, “Overexpression of the trk Tyrosone Kinase Rapidly Accelerates Nerve Growth Factor-Induced Differentiation,” Neuron (1992), vol. 9, pp. 883-896.
Hongo, et al., “Development and Characterization of Novel TRK—a Specific Monoclonal Antibodies,” Society for Neuroscience (1996), vol. 22, p. 1010.
Hongo, et al., “Development and Characterization of Murine Monoclonal Antibodies to the Latency-Associated Peptide of Transforming Growth Factor β1,” Hybridoma (1995), vol. 14, No. 3, pp. 253-260.
Inagaki, et al., “TrkA Tyrosine Residues Involved in NGF-induced Neurite Outgrowth of PC12 Cells”, European Journal of Neuroscience (1995), vol. 7, pp. 1125-1133.
Klesse, et al., “Nerve growth factor induces survival and differentiation through two distinct signaling cascades in PC12 cells,” Oncogene (1999), vol. 18, pp. 2055-2068.
Lee and Chao, “Activation of Trk neurotrophin receptors in the absence of neurotrophins,” Proc. Natl. Acad. Sci. (2001), vol. 98, No. 6, pp. 3555-3560.
Minichiello, et al., “Mechanisms of TrkB-Mediated Hippocampal Long-Term Potentiation,” Neuron (2002), vol. 36, pp. 121-137.
Oskam, et al., “Frequent generation of oncogenes by in vitro recombination of TRK protooncogene sequences,” Proc. Natl. Acad. Sci. USA (1988), vol. 85, pp. 2964-2968.
Pesavento, et al., “Blocking the NGF-TrkA Interaction Rescues the Developmental Loss of LTP in the Rat Visual Cortex: Rose of the Cholinergic System,” Neuron (2000), vol. 25, pp. 165-175.
Rakhit, et al., “Nerve Growth Factor Stimulation of p42/p44 Mitogen-Activated Protein Kinase in PC12 Cells: Role of Gi/o, G Protein-Coupled Receptor Kinase 2, β-Arrestin I, and Endocytic Processing,” Molecular Pharmacology (2001), vol. 60, pp. 63-70.
Rende, et al., “Nerve growth factor (NGF) influences differentiation and proliferation of myogenic cells in vitro via TrKA,” Int. J. Devl Neuroscience (2000), vol. 18, pp. 869-885.
Sadick, et al., “Analysis of Neurotrophim/Receptor Interactions with a gD-Flag-Modified Quantitative Kinase Receptor Activation (gD.KIRA) Enzyme-Linked Immunosorbent Assay,” Experimental Cell Research (1997), vol. 234, pp. 354-361.
Sadick, et al., “Analysis of Heregulin-Induced ErbB2 Phosphorylation with a High-Throughput Kinase Receptor Activation Enzyme-Linked Immunosorbant Assay,” Analytical Biochemistry (1996), vol. 235, pp. 207-214.
Urfer, et al., “High Resolution Mapping of the Binding Site of TrkA for Nerve Growth Factor and TrkC for Neurotrophin-3 on the Second Immunoglobulin-like Domain of the Trk Receptors,” The Journal of Biological Chemistry (1998), vol. 273, pp. 5829-5840.
Xiao, et al., “Variant PC12 Cell Line That Spontaneously Differentiates and Extends Neuritic Processes,” Journal of Neuroscience Research (2002), vol. 69, pp. 104-109.
Zola, Monoclonal Antibodies, CRC Press, Inc., Boca Raton, FL (1987).
Definition of “antagonist” from On-line Medical Dictionary, Nov. 18, 1997, http://cancerweb.ncl.ac.uk/cgi-bin/omd?query=antagonist&action=Search+OMD, Published at the Centre for Cancer Education, University of Newcastle upon Tyne, The CancerWEB Project, copyright 1997-2005.
Bedian, Vahe, Declaration regarding European Patent No. 1181318 in the name of Lay Line Genomics SpA, pp. 1-3, dated Jul. 2, 2009.
Benigni, Fabio, “Declaration of Dr. Fabio Benigni,” regarding European Patent No. 1181318 in the name of Lay Line Genomics SpA, pp. 1-22, submitted Jul. 3, 2009.
Thress, Kenneth, Declaration regarding European Patent No. 1181318 in the name of Lay Line Genomics SpA, dated Jun. 26, 2009.
Edwards Angell Palmer & & Dodge LLP
Lauro, Esq. Peter C.
Lay Line Genomics S.p.A.
Saoud Christine J
Wang Chang-Yu
LandOfFree
Monoclonal antibodies and antigen binding fragments thereof... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies and antigen binding fragments thereof..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies and antigen binding fragments thereof... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4136304